Sinapic acidCAS# 530-59-6 |
- trans-Sinapic acid
Catalog No.:BCN0344
CAS No.:7362-37-0
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 530-59-6 | SDF | Download SDF |
| PubChem ID | 637775 | Appearance | Powder |
| Formula | C11H12O5 | M.Wt | 224.2 |
| Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | (E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid | ||
| SMILES | COC1=CC(=CC(=C1O)OC)C=CC(=O)O | ||
| Standard InChIKey | PCMORTLOPMLEFB-ONEGZZNKSA-N | ||
| Standard InChI | InChI=1S/C11H12O5/c1-15-8-5-7(3-4-10(12)13)6-9(16-2)11(8)14/h3-6,14H,1-2H3,(H,12,13)/b4-3+ | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Sinapic acid shows antibacterial, antioxidant, anti-inflammary, and cardiacprotective activities. Sinapic acid ameliorates hyperglycemia through PLC-PKC signals to enhance the glucose utilization in diabetic rats. Sinapic acid is a potentially useful agent for the protection against liver fibrosis and cirrhosis, it protects the rat liver from CCl4-induced inflammation, most likely by acting as a free radical scavenger and modulator of NF-κB p65 activation and proinflammatory cytokine expression. |
| Targets | PKC | GLUT | NF-kB | p65 | TNF-α | TGF-β/Smad | IL Receptor |
| In vitro | Sinapic acid protects heart against ischemia/reperfusion injury and H9c2 cardiomyoblast cells against oxidative stress.[Pubmed: 25511706]Biochem Biophys Res Commun. 2015 Jan 24;456(4):853-9.The present study was designed to evaluate antioxidant and cardioprotective potential of Sinapic acid (SA) against ischemia/reperfusion (I/R) injury. |
| In vivo | Antihyperglycemic action of sinapic acid in diabetic rats.[Pubmed: 24261449]J Agric Food Chem. 2013 Dec 11;61(49):12053-9.Sinapic acid is a hydroxycinnamic acid contained in plants. Effect of sinapic acid against dimethylnitrosamine-induced hepatic fibrosis in rats.[Pubmed: 23435910]Arch Pharm Res. 2013 May;36(5):608-18.Sinapic acid is a member of the phenylpropanoid family and is abundant in cereals, nuts, oil seeds, and berries. It exhibits a wide range of pharmacological properties. |
| Animal Research | Effect of sinapic acid against carbon tetrachloride-induced acute hepatic injury in rats.[Pubmed: 23494565]Arch Pharm Res. 2013 May;36(5):626-33.Acute hepatic inflammation is regarded as a hallmark of early stage fibrosis, which can progress to extensive fibrosis and cirrhosis. Sinapic acid is a phenylpropanoid compound that is abundant in cereals, nuts, oil seeds, and berries and has been reported to exhibit a wide range of pharmacological properties. |
Sinapic acid Dilution Calculator
Sinapic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 4.4603 mL | 22.3015 mL | 44.603 mL | 89.2061 mL | 111.5076 mL |
| 5 mM | 0.8921 mL | 4.4603 mL | 8.9206 mL | 17.8412 mL | 22.3015 mL |
| 10 mM | 0.446 mL | 2.2302 mL | 4.4603 mL | 8.9206 mL | 11.1508 mL |
| 50 mM | 0.0892 mL | 0.446 mL | 0.8921 mL | 1.7841 mL | 2.2302 mL |
| 100 mM | 0.0446 mL | 0.223 mL | 0.446 mL | 0.8921 mL | 1.1151 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Syringic acid
Catalog No.:BCN5699
CAS No.:530-57-4
- 2,6-Dimethoxy-1,4-benzoquinone
Catalog No.:BCN5698
CAS No.:530-55-2
- Deoxyvasicinone
Catalog No.:BCN5697
CAS No.:530-53-0
- L-Picein
Catalog No.:BCC8336
CAS No.:530-14-3
- Indomethacin
Catalog No.:BCC3794
CAS No.:53-86-1
- Dehydroepiandrosterone
Catalog No.:BCN2202
CAS No.:53-43-0
- Oxandrolone
Catalog No.:BCC5242
CAS No.:53-39-4
- Methylprednisolone acetate
Catalog No.:BCC9043
CAS No.:53-36-1
- Cocaine hydrochloride
Catalog No.:BCC5943
CAS No.:53-21-4
- Mitotane (Lsodren)
Catalog No.:BCC3815
CAS No.:53-19-0
- Estrone
Catalog No.:BCN2201
CAS No.:53-16-7
- Prednisone
Catalog No.:BCC4957
CAS No.:53-03-2
- CDI (1,1′-Carbonyldiimidazole)
Catalog No.:BCC2809
CAS No.:530-62-1
- Salinomycin
Catalog No.:BCC1916
CAS No.:53003-10-4
- Murralongin
Catalog No.:BCN5696
CAS No.:53011-72-6
- T-5224
Catalog No.:BCC5383
CAS No.:530141-72-1
- Scutebarbatine J
Catalog No.:BCN8134
CAS No.:960302-85-6
- Morellic acid
Catalog No.:BCN3073
CAS No.:5304-71-2
- 9,13-Epidioxy-8(14)-abieten-18-oic acid
Catalog No.:BCN1426
CAS No.:5309-35-3
- Dichotomin
Catalog No.:BCN2836
CAS No.:53093-47-3
- Androsin
Catalog No.:BCN3842
CAS No.:531-28-2
- Coniferin
Catalog No.:BCN5700
CAS No.:531-29-3
- Scopolin
Catalog No.:BCN5701
CAS No.:531-44-2
- 7-Methoxycoumarin
Catalog No.:BCN2707
CAS No.:531-59-9
Sinapic acid protects heart against ischemia/reperfusion injury and H9c2 cardiomyoblast cells against oxidative stress.[Pubmed:25511706]
Biochem Biophys Res Commun. 2015 Jan 24;456(4):853-9.
The present study was designed to evaluate antioxidant and cardioprotective potential of Sinapic acid (SA) against ischemia/reperfusion (I/R) injury. Cardiac functional recovery after I/R was evaluated by percentage rate pressure product (%RPP) and percentage coronary flow (%CF). Myocardial injury was evaluated by 2,3,5-triphenyltetrazolium chloride (TTC) staining and LDH enzyme leakage. Oxidative stress was estimated by lipid peroxidation level. eNOS protein expression in reperfused heart was assessed using Western blot method. Finally, in order to support the antioxidant effect of SA, in vitro protective potential of SA was assessed on H2O2-induced oxidative stress in H9c2 cardiomyoblast cells. The overall results demonstrated that I/R induced cardiac dysfunction, injury and oxidative stress was attenuated by SA treatment. Moreover, in vitro results also shown that, SA protects H9c2 cells from oxidative stress and modulates mitochondrial membrane permeability transition (MPT). In conclusion, coupled results from both in vivo and in vitro experiments have confirmed that SA with antioxidant role protects cardiac cells and its functions from I/R induced oxidative stress.
Effect of sinapic acid against carbon tetrachloride-induced acute hepatic injury in rats.[Pubmed:23494565]
Arch Pharm Res. 2013 May;36(5):626-33.
Acute hepatic inflammation is regarded as a hallmark of early stage fibrosis, which can progress to extensive fibrosis and cirrhosis. Sinapic acid is a phenylpropanoid compound that is abundant in cereals, nuts, oil seeds, and berries and has been reported to exhibit a wide range of pharmacological properties. In this study, we investigated the anti-inflammatory effect of Sinapic acid in carbon tetrachloride (CCl4)-induced acute hepatic injury in rats. Sinapic acid was administered orally (10 or 20 mg/kg) to rats at 30 min and 16 h before CCl4 intoxication. Sinapic acid treatment of rats reduced CCl4-induced abnormalities in liver histology, serum alanine transaminase and aspartate transaminase activities, and liver malondialdehyde levels. In addition, Sinapic acid treatment significantly attenuated the CCl4-induced production of inflammatory mediators, including tumor necrosis factor-alpha and interleukin-1beta mRNA levels, and increased the expression of nuclear factor-kappa B (NF-kappaB p65). Sinapic acid exhibited strong free radical scavenging activity in vitro. Thus, Sinapic acid protected the rat liver from CCl4-induced inflammation, most likely by acting as a free radical scavenger and modulator of NF-kappaB p65 activation and proinflammatory cytokine expression. Sinapic acid may thus have potential as a therapeutic agent for suppressing hepatic inflammation.
Effect of sinapic acid against dimethylnitrosamine-induced hepatic fibrosis in rats.[Pubmed:23435910]
Arch Pharm Res. 2013 May;36(5):608-18.
Sinapic acid is a member of the phenylpropanoid family and is abundant in cereals, nuts, oil seeds, and berries. It exhibits a wide range of pharmacological properties. In this study, we investigated the hepatoprotective and antifibrotic effects of Sinapic acid on dimethylnitrosamine (DMN)-induced chronic liver injury in rats. Sinapic acid remarkably prevented DMN-induced loss of body weight. This was accompanied by a significant increase in levels of serum alanine transaminase, aspartate transaminase, and liver malondialdehyde content. Furthermore, Sinapic acid reduced hepatic hydroxyproline content, which correlated with a reduction in the expression of type I collagen mRNA and histological analysis of collagen in liver tissue. Additionally, the expression of hepatic fibrosis-related factors such as alpha-smooth muscle actin and transforming growth factor-beta1 (TGF-beta1), were reduced in rats treated with Sinapic acid. Sinapic acid exhibited strong scavenging activity. In conclusion, we find that Sinapic acid exhibits hepatoprotective and antifibrotic effects against DMN-induced liver injury, most likely due to its antioxidant activities of scavenging radicals, its capacity to suppress TGF-beta1 and its ability to attenuate activation of hepatic stellate cells. This suggests that Sinapic acid is a potentially useful agent for the protection against liver fibrosis and cirrhosis.
Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats.[Pubmed:23178800]
Eur J Pharmacol. 2013 Jan 15;699(1-3):213-8.
Lipids and lipoproteins play a vital role in the pathogenesis of myocardial infarction. There are no studies reported on the protective effects of Sinapic acid on changes in electrocardiogram, lipids and lipoproteins in myocardial infarction. This study aims to evaluate the protective effects of Sinapic acid on cardiac hypertrophy, dyslipidaemia and alterations in lipoproteins and electrocardiogram in isoproterenol-induced myocardial infarcted rats. Rats were pre- and co-treated with Sinapic acid (12 mg/kg body weight) daily for a period of 10 days and were induced myocardial infarction with isoproterenol (100mg/kg body weight) on 9th and 10th day. Isoproterenol induced rats showed an increased level of serum cardiac troponin-T and elevated ST-segments. Increased levels of serum and heart cholesterol, triglycerides and free fatty acids were observed in isoproterenol induced rats. Isoproterenol also increased serum low density and very low density lipoprotein cholesterol and decreased high density lipoprotein cholesterol. The activity of liver 3-hydroxy-3-methyl glutaryl-coenzyme-A-reductase was elevated in isoproterenol induced rats. The in vitro study revealed the potent antioxidant activity of Sinapic acid. Pre- and co-treatment with Sinapic acid ameliorated cardiac hypertrophy, dyslipidemia and elevated ST-segments in isoproterenol induced myocardial infarcted rats. Thus, Sinapic acid prevented the alterations in the levels of lipids and lipoproteins by virtue of its antilipidaemic effect in isoproterenol induced myocardial infarcted rats.
Antihyperglycemic action of sinapic acid in diabetic rats.[Pubmed:24261449]
J Agric Food Chem. 2013 Dec 11;61(49):12053-9.
Sinapic acid is a hydroxycinnamic acid contained in plants. In an attempt to know the hyperglycemic effect of Sinapic acid, this study applied streptozotocin (STZ) to induce type 1-like diabetic rats and fed fructose-rich chow to induce type 2-like diabetic rats. Sinapic acid dose-dependently reduced the hyperglycemia of STZ-diabetic rats (9.8 +/- 1.8%, 11.6 +/- 0.7%, and 19.4 +/- 3.2% at 5 mg/kg, 10 mg/kg, and 25 mg/kg, respectively). Also, Sinapic acid attenuated the postprandial plasma glucose without changing plasma insulin in rats. Repeated treatment of Sinapic acid increased the gene expression of GLUT4 in soleus muscle of STZ-diabetic rats. Moreover, Sinapic acid enhanced glucose uptake into isolated soleus muscle and L6 cells (337.0 +/- 29.6%). Inhibition of phospholipase C (PLC) using U73122 (1.00 +/- 0.02 mug/mg protein) or protein kinase C (PKC) using chelerythrine (0.97 +/- 0.02 mug/mg protein) attenuated the Sinapic acid-stimulated glucose uptake (1.63 +/- 0.02 mug/mg protein) in L6 cells. Otherwise, the reduced glucose infusion rate (GIR) in fructose-rich chow-fed rats was also raised by Sinapic acid. Our results suggest that Sinapic acid ameliorates hyperglycemia through PLC-PKC signals to enhance the glucose utilization in diabetic rats.
